Human IL-23 antigen binding proteins
Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.
1. An isolated antigen binding protein that binds IL-23, comprising at least one heavy chain variable region comprising:
a CDRH1 of SEQ ID NO: 91;
a CDRH2 of SEQ ID NO:92; and
a CDRH3 of SEQ ID NO: 93; and
at least one light chain variable region comprising:
a CDRL1 of SEQ ID NO: 62;
a CDRL2 of SEQ ID NO:63; and
a CDRL3 of SEQ ID NO:64.
2. An isolated antigen binding protein that binds IL-23 comprising a heavy chain variable region comprising amino acid residues 31-35, 50-65 and 99-113 of SEQ ID NO:31; and a light chain variable region comprising amino acid residues 23-36, 52-58 and 91-101 of SEQ ID NO:1.
3. An isolated antigen binding protein that binds IL-23 comprising
a heavy chain variable region of SEQ ID NO: 31 and
a light chain variable region of SEQ ID NO: 1.
4. An isolated antigen binding protein of claim 1 , 2 or 3 wherein said antigen binding protein has at least one property selected from the group consisting of:
a) reducing human IL-23 activity;
b) reducing production of a proinflammatory cytokine;
c) binding to human IL-23 with a K D of less than or equal to 5×10 −8 M;
d) having a K off rate of less than or equal to 5×10 −6 l/s; and
e) having an IC 50 of less than or equal to 400 pM.
5. A pharmaceutical composition comprising at least one antigen binding protein of claim 1 , 2 , or 3 and a pharmaceutically acceptable excipient.
6. A pharmaceutical composition comprising at least one antigen binding protein of claim 4 and a pharmaceutically acceptable excipient.